Home » Drug Information » Recently Approved Drugs » 1997
Medical Areas: Ophthalmology
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Allergan
Approval Status: Approved November 1997
Treatment Area: post-surgical inflammation following cataract extraction
Acular has now been approved by the FDA for post-surgical
inflammation following cataract extraction. Acular is administered
between one and four times daily starting 24 hours after surgery
for two weeks. It can be used with antibiotics, beta blockers,
carbonic anhydrase inhibitors, cycloplegics, and mydriatics. For
itch, Acular is administered between one and four times daily as
needed.
Adverse events include transient stinging and burning upon
application.
Acular (ketorolac tromethamine ophthalmic solution 0.5%) works
by inhibiting prostaglandins in the aqueous humor. Allergan began
marketing Acular in 1992 to treat seasonal conjunctival allergies,
although the drug did find off-label uses for cystoid macular
edemas and post-surgical inflammation.